Similar articles for PMID: 30443292

Year	Number of Results
1999	1
2003	1
2004	1
2008	1
2010	2
2012	3
2013	8
2014	10
2015	4
2016	16
2017	17
2018	12
2019	11
2020	10
2021	9
2022	5
2023	1
2024	0

1

Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with long-term outcome and prognostic factors.

Ottaiano A, Scotti V, De Divitiis C, Capozzi M, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Vicario V, De Stefano A, Tafuto S, Berretta M, Nasti G, Avallone A. Ottaiano A, et al. Oncotarget. 2018 Oct 16;9(81):35251-35265. doi: 10.18632/oncotarget.25834. eCollection 2018 Oct 16. Oncotarget. 2018. PMID: 30443292 Free PMC article.

2

Response criteria in solid tumors (PERCIST/RECIST) and SUV_max in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy.

Pierson C, Grinchak T, Sokolovic C, Holland B, Parent T, Bowling M, Arastu H, Walker P, Ju A. Pierson C, et al. Radiat Oncol. 2018 Feb 27;13(1):34. doi: 10.1186/s13014-018-0980-7. Radiat Oncol. 2018. PMID: 29486779 Free PMC article.

3

Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.

Sager S, Akgün E, Uslu-Beşli L, Asa S, Akovali B, Sahin O, Yeyin N, Demir M, Abuqbeitah M, Gülsen F, Sayman H, Sönmezoglu K. Sager S, et al. Nucl Med Commun. 2019 May;40(5):461-468. doi: 10.1097/MNM.0000000000001014. Nucl Med Commun. 2019. PMID: 30896544

4

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

5

3'-Deoxy-3'-¹⁸F-Fluorothymidine and ¹⁸F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies.

Kim JE, Chae SY, Kim JH, Kim HJ, Kim TW, Kim KP, Kim SY, Lee JL, Oh SJ, Kim JS, Ryu JS, Moon DH, Hong YS. Kim JE, et al. Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1713-1722. doi: 10.1007/s00259-019-04330-7. Epub 2019 Apr 30. Eur J Nucl Med Mol Imaging. 2019. PMID: 31041456

6

Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.

Harris JP, Chang-Halpenny CN, Maxim PG, Quon A, Graves EE, Diehn M, Loo BW Jr. Harris JP, et al. Clin Lung Cancer. 2015 Nov;16(6):475-85. doi: 10.1016/j.cllc.2015.01.007. Epub 2015 Jan 31. Clin Lung Cancer. 2015. PMID: 25770888

7

Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.

Chiu KWH, Lam KO, An H, Cheung GTC, Lau JKS, Choy TS, Lee VHF. Chiu KWH, et al. BMC Cancer. 2018 Jul 31;18(1):776. doi: 10.1186/s12885-018-4687-9. BMC Cancer. 2018. PMID: 30064385 Free PMC article.

8

Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.

Mertens J, De Bruyne S, Van Damme N, Smeets P, Ceelen W, Troisi R, Laurent S, Geboes K, Peeters M, Goethals I, Van de Wiele C. Mertens J, et al. Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1214-22. doi: 10.1007/s00259-013-2421-z. Epub 2013 May 1. Eur J Nucl Med Mol Imaging. 2013. PMID: 23636802

9

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T. Zerizer I, et al. Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30. Eur J Nucl Med Mol Imaging. 2012. PMID: 22644713

10

Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer.

Nemeth Z, Wijker W, Lengyel Z, Hitre E, Borbely K. Nemeth Z, et al. Pathol Oncol Res. 2020 Oct;26(4):2683-2691. doi: 10.1007/s12253-020-00865-5. Epub 2020 Jul 13. Pathol Oncol Res. 2020. PMID: 32661836 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year